Presentation is loading. Please wait.

Presentation is loading. Please wait.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Published byEleanor Janel Pitts Modified over 6 years ago

Similar presentations

Presentation on theme: "Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in."— Presentation transcript:

1 Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in randomised trials in coronary artery disease. Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in randomised trials in coronary artery disease. (A) any ST, (B) definite ST and (C) in-device LLL. Mohamed Farag et al. Open Heart 2016;3:e000462 ©2016 by British Cardiovascular Society

Download ppt "Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in."

Similar presentations

The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.

The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.
DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation

Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation
Bioresorbable scaffold: the advent of a new era in percutaneous coronary revascularisation Clinical Data Update Ron Waksman, MD, FACC Director, Cardiovascular.

Bioresorbable scaffold: the advent of a new era in percutaneous coronary revascularisation Clinical Data Update Ron Waksman, MD, FACC Director, Cardiovascular.
Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.
Stenting of Coronary Arteries in Non Stress/Benestent Disease

Stenting of Coronary Arteries in Non Stress/Benestent Disease
Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.

Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.
Frequency of the different drug-eluting stent (DES) used over time (2008–2014) according to active drug component and carrier material (groups >1% only).

Frequency of the different drug-eluting stent (DES) used over time (2008–2014) according to active drug component and carrier material (groups >1% only).
American College of Cardiology Presented by Dr. Stephan Windecker

American College of Cardiology Presented by Dr. Stephan Windecker
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Steven T. W. van Haelst, MD, Stefanie M. O. Peeters Weem, MD, Frans L

Steven T. W. van Haelst, MD, Stefanie M. O. Peeters Weem, MD, Frans L
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Ana Rita Ramalho et al. JCIN 2017;10:

Ana Rita Ramalho et al. JCIN 2017;10:
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Similar presentations

Ads by Google